Neurological Supplies News
-
Showcase
Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders
On March 15th 2015, Tim Buckinx’ son said: “Papa, you work in digital, can’t you create a light that turns on when my brain switches off?” At ten years old, he was simply fed up with the daily impact of his refractory epilepsy. That pain became a vision, and that vision became the Belgian digital therapeutics company epihunter, aimed at enabling people with a brain ...
By Epihunter NV
-
Showcase
Empatica partnering with U.S. Army MRDC to deploy COVID-19 early detection wearable
BOSTON, Nov. 6, 2020 /PRNewswire/ -- Empatica has been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to deploy a wearable and algorithm that enable the early and pre-symptomatic detection of COVID-19. The project's focus is on protecting the health of the general population by preventing outbreaks via early detection and alerting. Empatica's Aura algorithm gives a ...
-
Showcase
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...
By BCC Research
-
NHL Alumni Association partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in former NHL Players
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
-
CANAQUEST Announces Award of European Cannabinoid Patent
We believe we can provide a safer alternative to other THC products providing the benefits without the negative psychiatric side effects. Pre-clinical trials have demonstrated the reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity, and gene vulnerability. CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a ...
-
CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health & Pharma for their 8th Annual Healthcare and Pharmaceutical Program
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
-
CanaQuest and Neeka Health Sign Agreement to Conduct Clinical Studies with Mentanine
Canaquest Medical Corp (OTC:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced the signing of a Master Service Agreement with Neeka Health (“Neeka”) that will encompass multiple clinical studies to evaluate the ...
-
gammaCore Sapphire Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium. CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout ...
-
electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum. Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum Date: Thursday, November ...
-
electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within selected managed care health systems. ...
-
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical Care Society’s (NCS) 20th Annual Meeting held in San Antonio, Texas on October 17 – 21, 2022 on the possible role of gammaCore (nVNS) in the acute treatment of Traumatic Brain Injury (TBI). The presentation is being given by Dr. Afshin ...
-
Flowonix Medical Inc. And Cerebral Therapeutics Announce World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...
-
What needs to notice when choosing laser hair removal treatment
Why remove hair? Everyone wants their skin to be clean and fair, but some women have thick body hair and dare not wear skirts, especially in summer, when people show their bodies. Because of the thick hair on their bodies, it has a great impact on their overall image and is easy to give to them. Their psychology has caused a great shadow. Some women have thick and slender lip hair, which looks ...
-
Canaquest Launches Mentanine (Cannabidiol + IP Formula) in the US via www.canaqueststore.com, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine (cannabidiol “CBD” + IP, Omega-3s, ...
-
CanaQuest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via www.canaqueststore.com, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
Canaquest Medical Corp (OTC Pink:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in ...
-
Checkpoint Surgical Announces Organizational Changes to Support the Company’s Rapid Growth in the Nerve Care Market Space
Checkpoint Surgical today announced the transition of Len Cosentino from President and CEO to the role of Founder and Executive Advisor. Additionally, several other organizational changes to support the company’s rapid growth have recently been made. Checkpoint Surgical makes surgical devices for intraoperative nerve care. Len Cosentino, who has served as President and CEO from Checkpoint ...
-
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder: A Double-Blind, Randomized, Sham-Controlled Pilot Study in the journal, Brain Stimulation. The ...
-
Research from Beacon Biosignals Presented at Alzheimer`s Association International Conference
Beacon Biosignals, a startup that applies AI to EEG to unlock precision medicine for neurological and psychiatric disorders, presented research at the Alzheimer's Association International Conference, which took place July 31–Aug. 4, 2022, in San Diego. Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard ...
-
Canaquest - Recent developments
Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September. Our first Clinical Study at OBI already achieved a 20% reduction in seizures……..we believe we can do better with our more concentrated ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you